# Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

> **NCT05352178** · PHASE3 · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 873 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Recurrent
- Prostate Cancer Metastatic
- Metastatic Cancer
- Oligometastatic Disease
- Oligometastasis
- Hormone Sensitive Prostate Cancer

## Interventions

- **OTHER:** Radiotherapy (SBRT) and/or surgery (metastasectomy)
- **DRUG:** Androgen deprivation therapy
- **DRUG:** Androgen receptor targeted therapy

## Key facts

- **NCT ID:** NCT05352178
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-20
- **Primary completion:** 2027-04-25
- **Final completion:** 2032-04-25
- **Target enrollment:** 873 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05352178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05352178, "Metastasis-directed Therapy for Oligorecurrent Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05352178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*